U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07450859) titled 'A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)' on Feb. 26.
Brief Summary: This is a Phase 2 study for BT5528 in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment.
The drug, BT5528, is designed to find a specific protein called EphA2.
The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive BT5528, and both they a...